Covaxin's efficacy shows immense strength of Atmanirbhar Bharat: ICMR chief

Bharat Biotech said that Covaxin had demostrated an interim efficacy of 81 per cent in preventing Covid-19 in late-stage clinical trials

The journey of completely indigenous coronavirus vaccine (Covaxin) in less than 8 months showcases the immense strength of Atmanirbhar Bharat (self-reliant India) to fight the odds and stand tall in the global public health community, said ICMR Director General Dr Balram Bhargava while commenting on the efficacy results of Bharat Biotech's vaccine candidate Covaxin.

The Hyderabad-based drug maker, Bharat Biotech, said on Wednesday that Covaxin had demostrated an interim efficacy of 81 per cent in preventing Covid-19 in late-stage clinical trials.

"This is also a testament to India’s emergence as a global vaccine superpower," the ICMR chief said.

The trials,